JP2010521536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521536A5 JP2010521536A5 JP2010500241A JP2010500241A JP2010521536A5 JP 2010521536 A5 JP2010521536 A5 JP 2010521536A5 JP 2010500241 A JP2010500241 A JP 2010500241A JP 2010500241 A JP2010500241 A JP 2010500241A JP 2010521536 A5 JP2010521536 A5 JP 2010521536A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- acid
- carnitine
- statin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000002253 acid Substances 0.000 claims 9
- 239000002220 antihypertensive agent Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 6
- RDHQFKQIGNGIED-MRVPVSSYSA-N Acetylcarnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 5
- 206010022489 Insulin resistance Diseases 0.000 claims 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960001722 verapamil Drugs 0.000 claims 3
- UCQFPOBWKJCOFS-HSZRJFAPSA-N C(CCCCCCCCCCCCCCC)[C@](O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(CCCCCCCCCCCCCCC)[C@](O)(C[N+](C)(C)C)CC([O-])=O UCQFPOBWKJCOFS-HSZRJFAPSA-N 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Loniten Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 2
- 229960003632 Minoxidil Drugs 0.000 claims 2
- 229960001597 Nifedipine Drugs 0.000 claims 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
- 229960000715 Nimodipine Drugs 0.000 claims 2
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N Nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 claims 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 230000001800 adrenalinergic Effects 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229960004166 diltiazem Drugs 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- GDLBFKVLRPITMI-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 claims 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2S)-1-[(2R,4R)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 claims 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- AOHMFUYIHARAGR-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;magnesium Chemical compound [Mg].[Mg].[Mg].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AOHMFUYIHARAGR-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 claims 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229940009098 Aspartate Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960002155 Chlorothiazide Drugs 0.000 claims 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 claims 1
- 229940107084 Chlorthalidone Drugs 0.000 claims 1
- 229960005025 Cilazapril Drugs 0.000 claims 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N Cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 1
- 229940030606 DIURETICS Drugs 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229960000873 Enalapril Drugs 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960003883 Furosemide Drugs 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 claims 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims 1
- 229960002474 Hydralazine Drugs 0.000 claims 1
- 229950009810 Indolapril Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical class OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 229960002394 Lisinopril Drugs 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 229940095060 MAGNESIUM TARTRATE Drugs 0.000 claims 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L Magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N Methyldopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims 1
- 229960000615 Methyldopa Drugs 0.000 claims 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
- 229960002237 Metoprolol Drugs 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims 1
- 229960004255 Nadolol Drugs 0.000 claims 1
- 229960001783 Nicardipine Drugs 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 229960002460 Nitroprusside Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N Ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 claims 1
- 229950008492 PENTOPRIL Drugs 0.000 claims 1
- 229960002582 Perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N Perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 206010034636 Peripheral vascular disease Diseases 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 Ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 240000006531 Strophanthus gratus Species 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 229960001288 Triamterene Drugs 0.000 claims 1
- 229940066528 Trichloroacetate Drugs 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N Zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000001396 anti-anti-diuretic Effects 0.000 claims 1
- 230000003276 anti-hypertensive Effects 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 229940083181 centrally acting adntiadrenergic agents Methyldopa Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229960001523 chlortalidone Drugs 0.000 claims 1
- 229960004042 diazoxide Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 claims 1
- 229960004553 guanabenz Drugs 0.000 claims 1
- -1 human Dorarajin Chemical compound 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- QUIOHQITLKCGNW-ODZAUARKSA-L magnesium;(Z)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C/C([O-])=O QUIOHQITLKCGNW-ODZAUARKSA-L 0.000 claims 1
- MUZDLCBWNVUYIR-UHFFFAOYSA-L magnesium;2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)C(O)C(O)C([O-])=O MUZDLCBWNVUYIR-UHFFFAOYSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- ASPOIVQEUUCDQT-UHFFFAOYSA-N nitroprusside Chemical compound O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N ASPOIVQEUUCDQT-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 claims 1
- 229960003343 ouabain Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229960002508 pindolol Drugs 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000035485 pulse pressure Effects 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- 229960003147 reserpine Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 claims 1
- 230000000261 vasodilator Effects 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 229960002769 zofenopril Drugs 0.000 claims 1
Claims (14)
- インスリン耐性を有する前糖尿病の対象において、2型糖尿病およびその臨床的合併症の発症を予防するまたは遅延させるための、血圧降下薬および/またはスタチンとアセチルL-カルニチンまたはその医薬上許容される塩とを組み合わせて含むことを特徴とする、医薬組成物。
- 重度のインスリン耐性を有する前糖尿病の対象において、2型糖尿病およびその臨床的合併症の発症を予防するまたは遅延させるための、血圧降下薬および/またはスタチンとアセチルL-カルニチンまたはその医薬上許容される塩とを組み合わせて含むことを特徴とする、医薬組成物。
- 血圧降下薬により既に処置しているインスリン耐性を有する前糖尿病の対象において、2型糖尿病およびその臨床的合併症の発症を予防するまたは遅延させるための、アセチルL-カルニチンまたはその医薬上許容される塩を含む医薬組成物であって、スタチンを含んでいてもよい医薬組成物。
- 血圧降下薬により既に処置している前糖尿病の対象において、高血圧を処置するための、アセチルL-カルニチンまたはその医薬上許容される塩を含む医薬組成物であって、スタチンを含んでいてもよい医薬組成物。
- 血圧降下薬により既に処置している前糖尿病の対象において、収縮期血圧を低下させるための、アセチルL-カルニチンまたはその医薬上許容される塩を含む医薬組成物であって、スタチンを含んでいてもよい医薬組成物。
- 血圧降下薬により既に処置している前糖尿病の対象において、脈圧を低下させるための、アセチルL-カルニチンまたはその医薬上許容される塩を含む医薬組成物であって、スタチンを含んでいてもよい医薬組成物。
- アセチルL-カルニチンの医薬上許容される塩が以下からなる群から選択される請求項1〜6のいずれかに記載の医薬組成物:塩化物、臭化物、オロト酸塩、アスパラギン酸塩、酸アスパラギン酸塩、酸クエン酸塩、マグネシウムクエン酸塩、リン酸塩、酸リン酸塩、フマル酸塩および酸フマル酸塩、マグネシウムフマル酸塩、乳酸塩、マレイン酸塩および酸マレイン酸塩、シュウ酸塩、酸シュウ酸塩、パモ酸塩、酸パモ酸塩、硫酸塩、酸硫酸塩、グルコースリン酸塩、酒石酸塩および酸酒石酸塩、グリセロリン酸塩、ムケート、マグネシウム酒石酸塩、2-アミノエタンスルホン酸塩、マグネシウム2-アミノエタンスルホン酸塩、メタンスルホン酸塩、コリン酒石酸塩、トリクロロ酢酸塩およびトリフルオロ酢酸塩。
- 糖尿病の合併症が以下からなる群から選択される、請求項1〜3のいずれかに記載の医薬組成物:糖尿病性網膜症、糖尿病性ニューロパチーおよび糖尿病性腎症を含む微小血管性合併症;アテローム性動脈硬化症、末梢血管障害を含む大血管性合併症;肥満;高血圧;心筋梗塞;卒中;多嚢胞性卵巣症候群;およびシンドロームX。
- 血圧降下薬が以下からなる群から選択される、請求項1〜8のいずれかに記載の医薬組成物:プラゾシンを含むアルファ 1 アドレナリン拮抗剤;プロプラノロール、ナドロール、チモロール、メトプロロール、ピンドロールを含むベータアドレナリン拮抗剤;ロスタフロキシンを含むウアバイン拮抗剤;ラベタロールを含むアルファ/ベータアドレナリン共通拮抗剤;グアネチジン、レセルピンを含むアドレナリン作動性神経遮断剤;クロニジン、メチルドパおよびグアナベンズを含むCNS作用性血圧降下剤;スピラプリル、エナラプリル、ラミプリル、ペリンドプリル、インドラプリル、リシノプリル、キナプリル、ペントプリル、シラザプリル、カプトプリル、ゾフェノプリル、ピバロプリルおよびホシノプリルを含むアンギオテンシン変換酵素(ACE)阻害剤;ロサルタンを含むアンギオテンシンII受容体拮抗剤;ニカルジピン、ニモジピン、ベラパミル、ジルチアゼム、ニフェジピンを含むカルシウムチャネル遮断剤;ヒドロクロロチアジド、クロルタリドン、フロセミド、トリアムテレンを含む利尿剤;ヒドララジン、ミノキシジル、ニトロプルシド、ジアゾキシド、ヒドララジン、ミノキシジル、ベラパミルを含む血管拡張剤。
- カルシウムチャネル遮断剤がジルチアゼム、ニフェジピン、ベラパミル、ニカルジピンおよびニモジピンから成る群から選択される、請求項9に記載の医薬組成物。
- スタチンが、シンバスタチン、ロバスタチン、フルバスタチン、プラバスタチン、アトルバスタチン、セリバスタチン、ロバスタチンおよびロスバスタチンからなる群から選択される、請求項1〜10のいずれかに記載の医薬組成物。
- スタチンがシンバスタチンである、請求項11に記載の医薬組成物。
- 錠剤、サシェ、カプセルまたはバイアルの形態における経口または非経口投与に適する、固体または液体形態である、請求項1〜12のいずれかに記載の医薬組成物。
- 単一の医薬形態である、または連続投与のために別個の容器中に存在する、請求項1〜13のいずれかに記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07104624.7 | 2007-03-21 | ||
EP07104624 | 2007-03-21 | ||
PCT/EP2008/053437 WO2008113862A2 (en) | 2007-03-21 | 2008-03-21 | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014180519A Division JP5974056B2 (ja) | 2007-03-21 | 2014-09-04 | インスリン耐性を有する前糖尿病患者における2型糖尿病およびその合併症の予防に有用な組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010521536A JP2010521536A (ja) | 2010-06-24 |
JP2010521536A5 true JP2010521536A5 (ja) | 2011-05-06 |
JP5982091B2 JP5982091B2 (ja) | 2016-08-31 |
Family
ID=38328657
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010500241A Expired - Fee Related JP5982091B2 (ja) | 2007-03-21 | 2008-03-21 | インスリン耐性を有する前糖尿病患者における2型糖尿病およびその合併症の予防に有用な組成物 |
JP2014180519A Expired - Fee Related JP5974056B2 (ja) | 2007-03-21 | 2014-09-04 | インスリン耐性を有する前糖尿病患者における2型糖尿病およびその合併症の予防に有用な組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014180519A Expired - Fee Related JP5974056B2 (ja) | 2007-03-21 | 2014-09-04 | インスリン耐性を有する前糖尿病患者における2型糖尿病およびその合併症の予防に有用な組成物 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8389574B2 (ja) |
EP (1) | EP2136798B1 (ja) |
JP (2) | JP5982091B2 (ja) |
KR (1) | KR20090120503A (ja) |
CN (1) | CN101663030B (ja) |
AU (1) | AU2008228192B2 (ja) |
BR (1) | BRPI0809034A8 (ja) |
CA (1) | CA2681185C (ja) |
CY (1) | CY1116872T1 (ja) |
DK (1) | DK2136798T3 (ja) |
EA (1) | EA018442B1 (ja) |
ES (1) | ES2546619T3 (ja) |
HK (1) | HK1139040A1 (ja) |
HR (1) | HRP20150936T1 (ja) |
HU (1) | HUE025394T2 (ja) |
IL (1) | IL201014A (ja) |
MX (1) | MX2009009966A (ja) |
MY (1) | MY151623A (ja) |
NZ (1) | NZ579767A (ja) |
PL (1) | PL2136798T3 (ja) |
PT (1) | PT2136798E (ja) |
SG (2) | SG10201507488RA (ja) |
SI (1) | SI2136798T1 (ja) |
WO (1) | WO2008113862A2 (ja) |
ZA (1) | ZA200907280B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8589106B2 (en) * | 2010-12-22 | 2013-11-19 | Roche Diagnostics Operations, Inc. | Calibration of a handheld diabetes managing device that receives data from a continuous glucose monitor |
KR20190043076A (ko) * | 2017-10-17 | 2019-04-25 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제 |
CN115068451A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 竹红菌素类化合物作为ltb4受体抑制剂的医药用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827C3 (de) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin |
IT1254314B (it) * | 1992-03-27 | 1995-09-14 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari. |
IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
US5925656A (en) * | 1995-04-10 | 1999-07-20 | Dr. Reddy's Research Foundation | Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
IT1293067B1 (it) * | 1997-07-01 | 1999-02-11 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico |
IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
US6281234B1 (en) * | 1998-05-12 | 2001-08-28 | American Home Products Corporation | (2-Acylaminothiazole-4-yl)acetic acid derivative |
IT1302289B1 (it) * | 1998-09-30 | 2000-09-05 | Univ Catania | Composizioni farmaceutiche ad attivita' antineoplastica |
WO2000074675A1 (en) * | 1999-06-08 | 2000-12-14 | Sigma-Tau Industrie Farmaceutiche S.P.A. | Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines |
ITRM20010294A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
WO2003028747A1 (en) * | 2001-10-04 | 2003-04-10 | Harris Dennis H | Ingestible nerve and circulatory nutritional formulation |
-
2008
- 2008-03-21 CA CA2681185A patent/CA2681185C/en not_active Expired - Fee Related
- 2008-03-21 MX MX2009009966A patent/MX2009009966A/es active IP Right Grant
- 2008-03-21 PL PL08718141T patent/PL2136798T3/pl unknown
- 2008-03-21 KR KR1020097020878A patent/KR20090120503A/ko not_active Application Discontinuation
- 2008-03-21 AU AU2008228192A patent/AU2008228192B2/en not_active Ceased
- 2008-03-21 SG SG10201507488RA patent/SG10201507488RA/en unknown
- 2008-03-21 US US12/532,379 patent/US8389574B2/en not_active Expired - Fee Related
- 2008-03-21 ES ES08718141.8T patent/ES2546619T3/es active Active
- 2008-03-21 MY MYPI20094017 patent/MY151623A/en unknown
- 2008-03-21 WO PCT/EP2008/053437 patent/WO2008113862A2/en active Application Filing
- 2008-03-21 EP EP08718141.8A patent/EP2136798B1/en active Active
- 2008-03-21 JP JP2010500241A patent/JP5982091B2/ja not_active Expired - Fee Related
- 2008-03-21 SI SI200831494T patent/SI2136798T1/sl unknown
- 2008-03-21 EA EA200970877A patent/EA018442B1/ru not_active IP Right Cessation
- 2008-03-21 CN CN200880012860XA patent/CN101663030B/zh not_active Expired - Fee Related
- 2008-03-21 HU HUE08718141A patent/HUE025394T2/en unknown
- 2008-03-21 BR BRPI0809034A patent/BRPI0809034A8/pt not_active Application Discontinuation
- 2008-03-21 DK DK08718141.8T patent/DK2136798T3/en active
- 2008-03-21 NZ NZ579767A patent/NZ579767A/en not_active IP Right Cessation
- 2008-03-21 PT PT87181418T patent/PT2136798E/pt unknown
- 2008-03-21 SG SG2012019618A patent/SG193655A1/en unknown
-
2009
- 2009-09-17 IL IL201014A patent/IL201014A/en active IP Right Grant
- 2009-10-19 ZA ZA200907280A patent/ZA200907280B/xx unknown
-
2010
- 2010-05-14 HK HK10104708.3A patent/HK1139040A1/xx not_active IP Right Cessation
-
2014
- 2014-09-04 JP JP2014180519A patent/JP5974056B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-07 HR HRP20150936TT patent/HRP20150936T1/hr unknown
- 2015-09-11 CY CY20151100793T patent/CY1116872T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2273985A2 (en) | Capsule for the prevention of cardiovascular diseases | |
JP2009120619A (ja) | 心不全の予防又は治療のための医薬組成物 | |
EA019471B1 (ru) | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан | |
JP2010518169A (ja) | 心血管疾患の処置のためのラノラジンの使用 | |
JP6068765B2 (ja) | 薬学的複合製剤 | |
JP4705564B2 (ja) | 洞房結節If電流阻害剤およびアンギオテンシン変換酵素阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
US20100239669A1 (en) | Combinations of statins and anti-obesity agent | |
JP2010521536A5 (ja) | ||
EP1827448A1 (en) | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors | |
JP2004519424A5 (ja) | インシュリン分泌促進剤およびHMG−Co−Aレダクターゼ阻害剤およびACE阻害剤から選択される活性成分を含む組み合わせ | |
JPWO2006132091A1 (ja) | 新規なトリグリセリド低下剤 | |
UA122908C2 (uk) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА МІСТИТЬ ІНГІБІТОР ГМГ-КoА-РЕДУКТАЗИ ТА ІНГІБІТОР АПФ | |
JP2005525391A5 (ja) | ||
ES2364189T3 (es) | Compuesto útil para la prevención y tratamiento de hipertrofia ventricular izquierda en pacientes dializados. | |
JP2006523685A5 (ja) | ||
AU2003211195B2 (en) | Citalopram for the treatment of elevated blood pressure | |
CN1237971C (zh) | 含血管紧张素转换酶抑制剂、钙离子拮抗剂和艾司唑仑的复方降压制剂 | |
EA032808B1 (ru) | Дозированная лекарственная форма, содержащая бисопролол и периндоприл | |
RU2002133205A (ru) | Новый препарат | |
CN1473042A (zh) | 药物组合物 | |
KR20220166205A (ko) | 약학적 복합 제제 및 제조 방법 | |
JP2010241710A (ja) | Ace2活性誘導剤 | |
JP2006063066A (ja) | 抗動脈硬化作用を有する医薬組成物 |